[Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics]
- PMID: 19616395
- DOI: 10.1016/j.medmal.2009.06.007
[Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics]
Abstract
Objective: The aim of this study was to determine the antimicrobial activity of amoxicillin-clavulanic acid against Escherichia coli urinary strains, especially those resistant to amoxicillin, and to analyze the results according to the susceptibility testing methods.
Method: This prospective study was made from April to May 2008, on 301 E. coli strains isolated from urine samples. The susceptibility to antibiotics was studied by agar disk diffusion according to French Society of Microbiology Antibiogram Committee recommendations. MIC were determined with the E-test.
Results: According to the antibiogram, 59.8% of strains were resistant to amoxicillin, 33.2% to amoxicillin-clavulanic acid, 1.7% to cefotaxim, 8.3% to nalidixic acid, 6.6% to ofloxacin, 4.7% to ciprofloxacin, 4.7% to gentamicin and 38.1% to cotrimoxazole. After determining the MIC of E. coli strains resistant to amoxicillin and susceptible to amoxicillin-clavulanic acid, 37.5% (n=30) remained susceptible, 61.25% (n=55) were of intermediate susceptibility and only one strain (1.25%) was resistant. Among E. coli strains resistant to amoxicillin and intermediately susceptible to amoxicillin-clavulanic acid, 83.3% (n=55) remained intermediately susceptible, 13.7% (n=9) became susceptible and two strains (3%) were resistant.
Conclusion: The susceptibility testing methods, especially for amoxicillin-clavulanic acid, must be standardized to avoid the discrepancies noted between standard antibiograms and an accurate determination of MIC.
Similar articles
-
Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.Clin Ther. 2005 Jul;27(7):1043-9. doi: 10.1016/j.clinthera.2005.07.001. Clin Ther. 2005. PMID: 16154483 Clinical Trial.
-
Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.Int J Infect Dis. 2004 Nov;8(6):362-73. doi: 10.1016/j.ijid.2004.02.005. Int J Infect Dis. 2004. PMID: 15494258
-
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492718
-
[Lower urinary tract infections: bacterial epidemiology and recommendations].Prog Urol. 2008 Feb;18(1 Suppl FMC):F11-4. Prog Urol. 2008. PMID: 18773847 Review. French.
-
[Interest of amoxicillin-clavulanic acid combination in urology: An update].Prog Urol. 2016 Jun;26(8):437-41. doi: 10.1016/j.purol.2016.05.002. Epub 2016 Jun 22. Prog Urol. 2016. PMID: 27344075 Review. French.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous